Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker.

European journal of clinical pharmacology - 1 Sept 2009

Noehr-Jensen L, Zwisler S T, Larsen F, Sindrup S H, Damkier P, Nielsen F, Brosen K

Abstract excerpt

PURPOSE: To investigate the impact of cytochrome P450 2C19 (CYP2C19) phenotypes on escitalopram metabolism and to evaluate pupillometry as a serotonergic biomarker. METHODS: This was a double-blind, crossover design study with single and multiple doses of 10 mg escitalopram and placebo in panels of CYP2C19 extensive (EM) and poor metabolisers (PM). Pupillometry was measured by a NeurOptics Pupillometer-PLR....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Citalopram

Share to Cross-Over Studies

Share to Cytochrome P-450 CYP2C19

Share to Denmark

Share to Double-Blind Method

Share to Selective Serotonin Reuptake Inhibitors

Source

Identifiers

PMID: 19404631
DOI: 10.1007/s00228-009-0657-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker.PMID 19404631Read ↗

Impact of CYP2C19 Phenotype on Escitalopram Response in Geriatrics: Based on Physiologically-Based Pharmacokinetic Modeling and Clinical Observation.Semantic proximity Read ↗

CYP2C19 variation, not citalopram dose nor serum level, is associated with QTc prolongation.Semantic proximity Read ↗

Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis.Semantic proximity Read ↗

Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 study.Semantic proximity Read ↗

Pharmacokinetics and pharmacodynamics of etizolam are influenced by polymorphic CYP2C19 activity.Semantic proximity Read ↗

Pharmacogenetics to Predict Adverse Events Associated With Antidepressants.Semantic proximity Read ↗

Effect of CYP2C19 Pharmacogenetic Testing on Predicting Citalopram and Escitalopram Tolerability and Efficacy: A Retrospective, Longitudinal Cohort StudySemantic proximity Read ↗

Large-scale analysis demonstrates the influence of CYP2C19 genotype on specific SSRI side effects.Semantic proximity Read ↗

Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action.Semantic proximity Read ↗

CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline.Semantic proximity Read ↗

The effects of tramadol on static and dynamic pupillometry in healthy subjects--the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status.Semantic proximity Read ↗

Preliminary Evidence for Sex Differences in CYP2C19 Metabolic Capacity During Psychotropic Drug Treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.